BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang Q, Wu H, Nie L, Shi J, Lebenthal A, Chen J, Sun Q, Yang J, Huang L, Ye Q. Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases. Am J Surg Pathol. 2013;37:467-483. [PMID: 23426118 DOI: 10.1097/PAS.0b013e31826d2639] [Cited by in Crossref: 49] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Kawazoe T, Saeki H, Edahiro K, Korehisa S, Taniguchi D, Kudou K, Nakanishi R, Kubo N, Ando K, Nakashima Y, Oki E, Fujiwara M, Oda Y, Maehara Y. A case of mixed adenoneuroendocrine carcinoma (MANEC) arising in Barrett's esophagus: literature and review. Surg Case Rep 2018;4:45. [PMID: 29740725 DOI: 10.1186/s40792-018-0454-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
2 Bo H, Huang YQ. One case of neuroendocrine carcinoma of the esophagus with symptoms of lumbar spinal metastasis as initial manifestation. Shijie Huaren Xiaohua Zazhi 2016; 24(14): 2286-2288 [DOI: 10.11569/wcjd.v24.i14.2286] [Reference Citation Analysis]
3 Zhang Y, Li C, Chen M. Prognostic value of immunohistochemical factors in esophageal small cell carcinoma (ESCC): analysis of clinicopathologic features of 73 patients. J Thorac Dis 2018;10:4023-31. [PMID: 30174845 DOI: 10.21037/jtd.2018.06.26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
4 Yuan G, Zhan C, Zhu D, Xie H, Wei T, Lu T, Yang Y, Zhu Y, Wang Q. Population-based analysis of esophageal large cell neuroendocrine carcinoma between 2004 and 2015. J Thorac Dis 2019;11:5480-8. [PMID: 32030267 DOI: 10.21037/jtd.2019.11.34] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Watson GA, Ahmed Y, Picardo S, Chew S, Cobbe S, Mahony C, Crotty J, Wallis F, Shelly MJ, Kiely P, Ipadeola OB, Healy V, Osman N, Gupta RK. Unusual Sites of High-Grade Neuroendocrine Carcinomas: A Case Series and Review of the Literature. Am J Case Rep. 2018;19:710-723. [PMID: 29915166 DOI: 10.12659/ajcr.908953] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Babu Kanakasetty G, Dasappa L, Lakshmaiah KC, Kamath M, Jacob LA, Mallekavu SB, Rajeev LK, Haleshappa RA, Kadabur Nagendrappa L, Saldanha SC, Kumar RV. Clinicopathological Profile of Pure Neuroendocrine Neoplasms of the Esophagus: A South Indian Center Experience. J Oncol. 2016;2016:2402417. [PMID: 27340404 DOI: 10.1155/2016/2402417] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
7 Gao A, Wang L, Li J, Li H, Han Y, Ma X, Sun Y. Prognostic Value of Perineural Invasion in Esophageal and Esophagogastric Junction Carcinoma: A Meta-Analysis. Dis Markers 2016;2016:7340180. [PMID: 27051075 DOI: 10.1155/2016/7340180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
8 Singhi AD, Seethala RR, Nason K, Foxwell TJ, Roche RL, McGrath KM, Levy RM, Luketich JD, Davison JM. Undifferentiated carcinoma of the esophagus: a clinicopathological study of 16 cases. Hum Pathol 2015;46:366-75. [PMID: 25582499 DOI: 10.1016/j.humpath.2014.11.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
9 Tustumi F, Marques SSB, Barros EF, Henriques AC, Waisberg J, Dias AR. THE PROGNOSIS OF THE DIFFERENT ESOPHAGEAL NEUROENDOCRINE CARCINOMA SUBTYPES: A POPULATION-BASED STUDY. Arq Gastroenterol 2022;59:53-7. [DOI: 10.1590/s0004-2803.202200001-10] [Reference Citation Analysis]
10 Liu S, Ge X, Gao Z, Zhou Q, Shi Y, Jiang W, Yang M, Sun X. Clinicopathological analysis of 67 cases of esophageal neuroendocrine carcinoma and the effect of postoperative adjuvant therapy on prognosis. Medicine (Baltimore) 2021;100:e27302. [PMID: 34713821 DOI: 10.1097/MD.0000000000027302] [Reference Citation Analysis]
11 Bellizzi AM. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum Pathol 2020;96:8-33. [PMID: 31857137 DOI: 10.1016/j.humpath.2019.12.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
12 Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M, Asa SL. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 2022;33:115-54. [PMID: 35294740 DOI: 10.1007/s12022-022-09708-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
13 Mastracci L, Rindi G, Grillo F, Solcia E, Campora M, Fassan M, Parente P, Vanoli A, La Rosa S. Neuroendocrine neoplasms of the esophagus and stomach. Pathologica 2021;113:5-11. [PMID: 33686305 DOI: 10.32074/1591-951X-229] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Parra-Medina R, Moreno-Lucero P, Jimenez-Moreno J, Parra-Morales AM, Romero-Rojas A. Neuroendocrine neoplasms of gastrointestinal tract and secondary primary synchronous tumors: A systematic review of case reports. Casualty or causality? PLoS One 2019;14:e0216647. [PMID: 31086397 DOI: 10.1371/journal.pone.0216647] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
15 Schizas D, Mastoraki A, Kirkilesis GI, Sioulas AD, Papanikolaou IS, Misiakos EP, Arkadopoulos N, Liakakos T. Neuroendocrine Tumors of the Esophagus: State of the Art in Diagnostic and Therapeutic Management. J Gastrointest Cancer. 2017;48:299-304. [PMID: 28656561 DOI: 10.1007/s12029-017-9978-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
16 Cai W, Ge W, Yuan Y, Ding K, Tan Y, Wu D, Hu H. A 10-year Population-based Study of the Differences between NECs and Carcinomas of the Esophagus in Terms of Clinicopathology and Survival. J Cancer. 2019;10:1520-1527. [PMID: 31031862 DOI: 10.7150/jca.29483] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
17 Nakao Y, Okino T, Yamashita YI, Taki K, Nakagawa S, Matsumoto K, Goto M, Baba H. Case report of aggressive treatments for large-cell neuroendocrine carcinoma of the esophagus. Int J Surg Case Rep 2019;60:291-5. [PMID: 31265990 DOI: 10.1016/j.ijscr.2019.06.056] [Reference Citation Analysis]
18 Kong ZZ, Zhang L. Esophagogastric junctional neuroendocrine tumor with adenocarcinoma: A case report. World J Clin Cases 2022; 10(18): 6241-6246 [DOI: 10.12998/wjcc.v10.i18.6241] [Reference Citation Analysis]
19 Robertson S, Patil DT. An Update on the Role of Immunohistochemistry in the Evaluation of Gastrointestinal Tract Disorders. Adv Anat Pathol 2020;27:193-205. [PMID: 30234501 DOI: 10.1097/PAP.0000000000000214] [Reference Citation Analysis]
20 Lee CG, Lim YJ, Park SJ, Jang BI, Choi SR, Kim JK, Kim YT, Cho JY, Yang CH, Chun HJ, Song SY; Neuroendocrine tumor study group. The clinical features and treatment modality of esophageal neuroendocrine tumors: a multicenter study in Korea. BMC Cancer. 2014;14:569. [PMID: 25098730 DOI: 10.1186/1471-2407-14-569] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
21 Doi S, Matsumoto S, Wakatsuki K, Migita K, Ito M, Kunishige T, Nakade H, Hatakeyama K, Ohbayashi C, Sho M. A neuroendocrine carcinoma with a well-differentiated adenocarcinoma component arising in Barrett's esophagus: a case report and literature review. Surg Case Rep 2018;4:103. [PMID: 30159830 DOI: 10.1186/s40792-018-0511-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
22 Fukui H, Dohi O, Miyazaki H, Yasuda T, Yoshida T, Ishida T, Doi T, Hirose R, Inoue K, Harusato A, Yoshida N, Uchiyama K, Ishikawa T, Takagi T, Konishi H, Morinaga Y, Itoh Y. A case of endoscopic submucosal dissection for neuroendocrine carcinoma of the esophagus with invasion to the muscularis mucosae. Clin J Gastroenterol 2022. [PMID: 35072903 DOI: 10.1007/s12328-022-01595-8] [Reference Citation Analysis]
23 Tang N, Feng Z. Endoscopic submucosal dissection combined with adjuvant chemotherapy for early-stage neuroendocrine carcinoma of the esophagus: A case report. World J Clin Cases 2022; 10(10): 3164-3169 [DOI: 10.12998/wjcc.v10.i10.3164] [Reference Citation Analysis]
24 Wang H, Chen Y, Pi G, Zhu Y, Yang S, Mei H, Lin Z, Zhang T. Validation and proposed modification of the 8th edition American Joint Committee on Cancer staging system for patients with esophageal neuroendocrine neoplasms: Evaluation of a revised lymph node classification. Oncol Lett. 2020;19:4122-4132. [PMID: 32382351 DOI: 10.3892/ol.2020.11480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Chin JL, O'Toole D. Diagnosis and Management of Upper Gastrointestinal Neuroendocrine Tumors. Clin Endosc. 2017;50:520-529. [PMID: 29207862 DOI: 10.5946/ce.2017.181] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
26 Ye L, Lu H, Wu L, Zhang L, Shi H, Wu HM, Tu P, Li M, Wang FY. The clinicopathologic features and prognosis of esophageal neuroendocrine carcinomas: a single-center study of 53 resection cases. BMC Cancer. 2019;19:1234. [PMID: 31852479 DOI: 10.1186/s12885-019-6420-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
27 Chen C, Hu H, Zheng Z, Yang Y, Chen W, Qiao X, Li P, Zhang S. Clinical characteristics, prognostic factors, and survival trends in esophageal neuroendocrine carcinomas: A population-based study. Cancer Med 2022. [PMID: 35596661 DOI: 10.1002/cam4.4829] [Reference Citation Analysis]
28 Ilett EE, Langer SW, Olsen IH, Federspiel B, Kjær A, Knigge U. Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics (Basel) 2015;5:119-76. [PMID: 26854147 DOI: 10.3390/diagnostics5020119] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 7.1] [Reference Citation Analysis]
29 Egashira A, Morita M, Kumagai R, Taguchi KI, Ueda M, Yamaguchi S, Yamamoto M, Minami K, Ikeda Y, Toh Y. Neuroendocrine carcinoma of the esophagus: Clinicopathological and immunohistochemical features of 14 cases. PLoS One. 2017;12:e0173501. [PMID: 28288180 DOI: 10.1371/journal.pone.0173501] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
30 Hong L, Zhang Y, Liu Z. Neuroendocrine carcinoma of esophageal and gastric cardia: clinicopathologic and immunohistochemistry study of 80 cases. Oncotarget. 2018;9:10754-10764. [PMID: 29535841 DOI: 10.18632/oncotarget.23610] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
31 Tulvatana W, Luemsamran P, Chumdermpadetsuk R, Keelawat S. Azzopardi Phenomenon in a Non-neoplastic Phthisical Eye: A Case Report. TOOPHTJ 2021;15:288-91. [DOI: 10.2174/1874364102115010288] [Reference Citation Analysis]
32 Matsunaga M, Daa T, Harada K, Okamura K, Noguchi T. Submucosal layer invasion of squamous cell carcinoma in situ and its differentiation to endocrine cell carcinoma in a case of superficial carcinoma at the esophagogastric junction. Int Canc Conf J 2015;4:111-6. [DOI: 10.1007/s13691-014-0181-7] [Reference Citation Analysis]
33 Hjerpe SJ, Rahim U, Usman MS, Ansari A, Chowdhury W, Lodhi MU, Rahim M. High-grade Non-small Cell Neuroendocrine Carcinoma of the Esophagus. Cureus 2018;10:e2416. [PMID: 29872597 DOI: 10.7759/cureus.2416] [Reference Citation Analysis]
34 Cai MY, Cardoso MF, Zhu Y, Zhong YS, Zhou PH. An esophageal submucosal tumor treated with submucosal tunneling endoscopic resection: an unexpected result. Gastroenterol Rep (Oxf) 2021;9:269-71. [PMID: 34316377 DOI: 10.1093/gastro/goaa073] [Reference Citation Analysis]
35 Deng HY, Ni PZ, Wang YC, Wang WP, Chen LQ. Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection. J Thorac Dis. 2016;8:1250-1256. [PMID: 27293844 DOI: 10.21037/jtd.2016.04.21] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
36 Tanaka Y, Hirata D, Fujii S, Kusaka T, Shibuya S. Early-stage Neuroendocrine Carcinoma of the Esophagus Observed with Annual Endoscopy for Three Years. Intern Med 2019;58:1727-31. [PMID: 30799355 DOI: 10.2169/internalmedicine.2151-18] [Reference Citation Analysis]
37 Wang MM, Singh SK. Rapidly Extensive Recurrence of Esophageal Neuroendocrine Carcinoma After Complete Pathologic Response to Definitive Chemoradiation. ACG Case Rep J 2022;9:e00730. [DOI: 10.14309/crj.0000000000000730] [Reference Citation Analysis]
38 Khonglah Y, Jitani AK, Gogoi BB, Hage N, Devi LP, Lynrah KG. Concurrent Lesions in Oesophagus: an Approach to Diagnosis with a Case Report. J Gastrointest Cancer 2017;48:201-4. [PMID: 27105636 DOI: 10.1007/s12029-016-9822-8] [Reference Citation Analysis]
39 Borbath I, Pape UF, Deprez PH, Bartsch DK, Caplin M, Falconi M, Garcia-Carbonero R, Grozinsky-Glasberg S, Jensen RT, Arnold R, Ruszniewski P, Toumpanakis C, Valle JW, O Toole D; Members of the Advisory Board of the European Neuroendocrine Tumor Society (ENETS). ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. J Neuroendocrinol 2022;:e13105. [PMID: 35233848 DOI: 10.1111/jne.13105] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
40 Fujihara S, Kobayashi M, Nishi M, Yachida T, Yoshitake A, Deguchi A, Muraoka A, Kobara H, Masaki T. Composite neuroendocrine carcinoma and squamous cell carcinoma with regional lymph node metastasis: a case report. J Med Case Rep. 2018;12:227. [PMID: 30139375 DOI: 10.1186/s13256-018-1775-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
41 Deng HY, Chen ZH, Wang ZQ, Wang YC, Li EM, Xu LY, Lin YD, Chen LQ. High expression of Ki-67 is an independent favorable prognostic factor for esophageal small cell carcinoma. Oncotarget 2017;8:55298-307. [PMID: 28903420 DOI: 10.18632/oncotarget.19426] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
42 Savva C, Kaye P, Soomro I, Parsons SL, James E, Madhusudan S. Primary Esophagogastric Neuroendocrine Carcinoma: a Retrospective Study from the Nottingham Upper Gastrointestinal Cancer Center. J Gastrointest Cancer 2018;49:85-92. [PMID: 29230683 DOI: 10.1007/s12029-017-0039-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
43 Lu ZH, Li J, Lu M, Zhang XT, Li J, Zhou J, Wang XC, Gong JF, Gao J, Li Y. Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas. Med Oncol. 2013;30:664. [PMID: 23864251 DOI: 10.1007/s12032-013-0664-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
44 Deng HY, Li G, Luo J, Li XR, Alai G, Lin YD. The Role of Surgery in Treating Resectable Limited Disease of Esophageal Neuroendocrine Carcinoma. World J Surg. 2018;42:2428-2436. [PMID: 29340724 DOI: 10.1007/s00268-018-4475-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]